Peptides Similar to Hexarelin

Peptides Related to Hexarelin#

Hexarelin belongs to the growth hormone releasing peptide (GHRP) family, a class of synthetic peptides that stimulate pituitary growth hormone release through activation of the GHS-R1a receptor (ghrelin receptor). Several related compounds share this mechanism but differ meaningfully in potency, selectivity, secondary hormonal effects, and ancillary pharmacological activities. The comparisons below draw on clinical and preclinical data to characterize the relative profiles of hexarelin and its closest analogs.

GHRP-2#

GHRP-2 (pralmorelin) is a synthetic hexapeptide GHS with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. Like hexarelin, it binds GHS-R1a to stimulate pituitary GH release and has been studied in Phase 2 clinical trials. GHRP-2 is generally considered the closest comparator to hexarelin in terms of GH-releasing potency, though hexarelin typically produces slightly higher peak GH levels in head-to-head assessments.

The principal distinction between the two compounds lies in selectivity. GHRP-2 demonstrates a more favorable selectivity profile, stimulating robust GH release with comparatively modest effects on cortisol and prolactin secretion. Hexarelin, while more potent for acute GH release, produces more pronounced elevations in cortisol (via ACTH stimulation) and prolactin. This difference has clinical implications for any potential chronic use, where sustained cortisol and prolactin elevation could produce adverse metabolic and endocrine effects.

Both compounds are subject to GH response desensitization with repeated administration, a class effect among GHRPs attributed to GHS-R1a downregulation and increased somatostatin tone. The rate and magnitude of desensitization appear broadly similar between hexarelin and GHRP-2, though direct long-term comparative data are limited.

A unique differentiator for hexarelin is its binding to the CD36 scavenger receptor, which mediates GH-independent cardioprotective effects. GHRP-2 does not demonstrate comparable CD36 activity, making hexarelin the preferred compound for research focused on cardiac protection through this pathway.

GHRP-6#

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is the earliest and most extensively studied member of the GHRP family. Structurally, it differs from hexarelin primarily at position 2, where it contains D-tryptophan without the 2-methyl modification found in hexarelin. This seemingly minor structural difference translates to meaningful pharmacological differences.

GHRP-6 is less potent than hexarelin for GH release on a per-dose basis. In clinical studies, hexarelin consistently produced higher peak GH concentrations than equimolar doses of GHRP-6, reflecting the enhanced GHS-R1a binding affinity conferred by hexarelin's 2-methyltryptophan residue.

The most notable clinical distinction of GHRP-6 is its more pronounced appetite-stimulating effect. GHRP-6 exhibits stronger ghrelin-mimetic activity at hypothalamic appetite centers, producing a robust increase in hunger that is greater than that observed with hexarelin, GHRP-2, or ipamorelin. This property can be advantageous in cachectic or anorexic conditions where appetite stimulation is desirable, but it represents a limitation in contexts where appetite increase is unwanted.

GHRP-6 also stimulates cortisol and prolactin secretion, though the magnitude is generally intermediate between hexarelin (higher) and ipamorelin (lower). Like hexarelin, GHRP-6 is subject to desensitization with chronic administration.

GHRP-6 has been reported to show some CD36 interaction in preclinical models, though this activity is generally considered weaker than that of hexarelin. The cardiovascular protective effects demonstrated with hexarelin through CD36 have not been as convincingly established for GHRP-6.

Ipamorelin#

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) represents a newer generation of GHS peptides designed for maximal GH selectivity. It is a pentapeptide that binds GHS-R1a with moderate affinity and stimulates GH release with minimal effects on cortisol, prolactin, aldosterone, and appetite. This selectivity profile distinguishes ipamorelin from hexarelin and the earlier GHRPs.

The trade-off for ipamorelin's superior selectivity is lower peak GH release potency compared to hexarelin. In comparative studies, hexarelin produces substantially higher acute GH peaks than ipamorelin at comparable doses. For applications where maximal GH stimulation is the primary objective, hexarelin offers a potency advantage. For applications where clean GH stimulation without secondary hormonal effects is preferred, ipamorelin is generally considered more suitable.

Ipamorelin does not demonstrate meaningful CD36 binding activity, lacking hexarelin's cardioprotective mechanism. This absence further differentiates the two compounds for cardiovascular research applications.

Desensitization with chronic ipamorelin use has been reported but may develop more slowly or to a lesser degree than with hexarelin, though direct long-term comparative desensitization data are limited.

Comparative Summary of GHS Peptides#

Non-Peptide GHS-R1a Agonists#

MK-0677 (ibutamoren) is an orally bioavailable non-peptide GHS-R1a agonist that represents an alternative approach to growth hormone secretagogue therapy. Unlike the GHRP peptides, MK-0677 can be administered orally due to its non-peptide structure, and it has a substantially longer half-life (approximately 4 to 6 hours), enabling once-daily dosing and sustained GH elevation.

MK-0677 produces robust GH release with associated increases in IGF-1, appetite stimulation, and modest effects on cortisol and prolactin. It has been studied in Phase 2 and Phase 3 trials for multiple indications including growth hormone deficiency, sarcopenia, and Alzheimer disease. Its development may have reduced commercial interest in advancing hexarelin and other injectable GHS peptides, given the convenience advantages of oral administration.

Hexarelin retains a potential advantage over MK-0677 in its CD36-mediated cardioprotective activity, which has not been demonstrated for non-peptide GHS-R1a agonists, and in the ability to deliver controlled pulsatile GH stimulation through timed injections, which more closely mimics the physiological pattern of GH secretion.

GHRH Analogs: Tesamorelin and CJC-1295#

Tesamorelin and CJC-1295 are analogs of growth hormone-releasing hormone (GHRH) that stimulate GH release through the GHRH receptor rather than GHS-R1a. They operate through an entirely different receptor system and signaling pathway compared to hexarelin and the GHRPs. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, making it the only approved compound in the broader GH secretagogue space.

The mechanistic distinction is pharmacologically significant because hexarelin and GHRH analogs act synergistically when co-administered, producing GH responses that exceed the sum of individual responses. This synergy arises from their complementary actions: hexarelin stimulates GH release through GHS-R1a activation at the pituitary while simultaneously suppressing somatostatin at the hypothalamic level, and GHRH analogs directly activate somatotrophs through the GHRH receptor. This synergistic interaction has been exploited in diagnostic testing to assess pituitary GH reserve.

Considerations for Research Application Selection#

The choice among GHS peptides depends on the research objective. Hexarelin is best suited for studies requiring maximal acute GH stimulation, investigations of CD36-mediated cardioprotection, or exploration of GHS-R1a pharmacology at high receptor occupancy. GHRP-2 offers a favorable compromise between potency and selectivity for GH-focused research without the confounding effects of cortisol and prolactin elevation. Ipamorelin is optimal for studies isolating GH effects from secondary hormonal changes. GHRP-6 is relevant where appetite stimulation is a desired endpoint or where the longest available research history is valued.

No head-to-head randomized clinical trials comparing the long-term efficacy and safety of these compounds have been published, and all comparisons rely on separate studies with differing methodologies, populations, and endpoints. Direct comparative data, particularly regarding desensitization kinetics and cardiovascular outcomes, represent important gaps in the GHS peptide literature.

Related Reading#

• Hexarelin overview and research guide
• Hexarelin research evidence
• Hexarelin dosing protocols